If the company manages to get a go-ahead from the regulator for this plant, it might result in resumption of supplies of several of their products, barred from the US last year.
Roadblocks ahead as these medicines could face new clinical tests, more scrutiny
The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.
Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.
.jpg)
The Drugs Controller General of India is considering the recommendations of its advisory body to revoke the suspension of the sale of analgin-based medicines in the country.
The company has identified India as one of the two key markets in South Asia.
.jpg)
In the process, Vodafone India's valuation rose 48.39 per cent since February 2012, when Piramal Enterprises bought 5.5 per cent stake in Vodafone India for Rs 3,007 crore (Rs 30.07 billion).
Move follows a spate of international regulatory enforcements on Indian drug firms.
Have committed themselves to investing Rs 1,85,000 crore since last year.
Importers protest as food safety regulator demands adherence to recent law on labelling, blocks entry at ports for packs with stickers.
According to the CEO of an Indian group with presence in the telecom segment and two merchant bankers, the Mexico-headquartered telco's bankers have been sounded out for preliminary discussions with leading Indian telecom companies for a strategic tie-up.
DoT plans to initiate move that might lower the revenues telcos share with government.
Govt wants firms to remove suffixes & prefixes to original names of these drugs.
The Indian Pharmaceutical Alliance has approached regulator for a dialogue to understand the concern raised by it
Say heavy penalties for medical errors might raise health care costs and make practitioners too cautious, says Sushmi Dey
As many as 150 applications are stuck at evaluation stage, says official.
Ranbaxy's US factory, Ohm Laboratories, is learnt to have got a clean chit from the American regulator. This US facility was under surveillance of the Food and Drug Administration (FDA) since the end of 2012.
Happy hours, a discount concept popular across bars, restaurants and multiplexes, is now catching up in the health care sector, too.
The country's drug companies have attracted the highest number of enforcements from the American drug regulator in 2013, a year that has seen the US Food and Drug Administration turning stricter to ensure compliance levels and quality of medicines.
DCGI, health ministry initiate dialogues with foreign regulators, try to understand global best practices
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances